Table 1 Primary tumor volumetric changes in HNSCC or NPC during curative RT or CRT

Bhide IJROBP 2010 [8]

20 (10 OPC, 6 Laryng or Hypoph, 4 NPC)

Weeks 2, 3, 4, 5

3.2% CTV1, where CTV1 was gross disease + 1.5 cm margin (0.74–5.6%)

–

–

Liu IJROBP 2018 [9]

18 (16 OPC, 1 NPC, 1 UP)

Fx 10 and 22

16.4% GTV, 15.4% CTV1 where CTV1 was GTV + 0.5 cm margin (GTV − 2.1 to 37.1%, CTV1 0.7 to 30.5%)

–

32.6% GTV, 28.2% CTV1 by fraction 22 (GTV 9.8 to 56.3%, CTV1 12.0 to 44.8%)

Capelle Clin Oncol 2012 [10]

20 (17 HNSCC, 3 NPC)

Fx 15

–

28.8% GTV, 16% PTV60/66 where PTV60 was a 0.5 cm expansion on CTV60 (involved postop regions) for adjuvant patients and PTV66 was a 0.5 cm expansion on the GTV for definitive patients (GTV 1.6 to 60%, PTV 0 to 45%)

–

Chitapanarux J Radiat Res 2015 [11]

17 (17 NPC)

Fx 17

–

18.4% GTV, − 7.4% CTV70 by fraction 17 where CTV70 was GTV + 0.5 cm margin (range NS)

–

Dewan Asian Pac J 2016 [12]

30 (15 OPC, 10 OC, 5 Hypoph)

Fx 20

–

47.62% GTV, 43.76% CTV where CTV was GTV + 0.5–2 cm margin, 49.69% PTV where PTV was 0.2–0.5 cm margin by fraction 20 (range NS)

–

Lee Cancer Res Treat 2016 (13)

159 (159 NPC)

Fx 15

–

43.4% GTV (− 3.8 to 93.5%)

–

Lu Chin Med J 2012 [14]

43 (43 NPC)

Fx 20

–

30.1% GTV by Fraction 20 (0.6 to 77.2%)

–

Mahmoud Technol Cancer Res Treat 2017 [15]

22 (11 OPC, 7 OC, 2 Laryng, 1 Hypoph, 1 NPC)

Fx 15, 27

–

7.2% CTV-HR for definitive (− 3 to 18%) 7.8% CTV-HR for postoperative (0 to 18%) where CTV-HR “included the regions and/or subjacent lymph node chains within 2 to 3 cm of gross disease”

12.8% CTV-HR for definitive (−7 to 29%) 10.9% CTV-HR for postoperative (3 to 20%)

Surucu Technol Cancer Res Treat 2016 [16]

48 (28 OPC, 7 NPC, 5 Hypoph, 8 OC)

Week 4 (median; rescans done at a median dose of 37.8Gy with range of 14.4–51.5 Gy)

–

26.8% GTV (range NS)

–

Surucu Technol Cancer Res Treat 2017 [27]

34 (20 OPC, 6 OC, 5 NPC, 3 Hypoph)

Week 4 (median; rescans done at a median dose of 37.8Gy with range of 27.0–48.6 Gy)

–

–

35.2% GTV (−18.8 to 79.6%)

Castelli Radiat Oncol 2015 [3]

15 (11 OPC, 2 OC, 1 Laryng, 1 Hypoph)

Weekly

–

–

31% CTV70 where CTV70 was GTV + 0.5 cm margin (−13 to 73%)

Loo Clin Oncol 2011 [17]

5 (3 OPC, 1 OC, 1 Laryng)

Weekly

–

–

5.8% CTV68 where CTV68 “encompassed the GTV and high-risk regions” (range NS)

Beltran J Appl Clin Med 2012 [18]

16 (7 OPC, 5 OC, 1 Hypoph, 1 NPC, 2 NS)

Fx 15, 25

–

–

13.25% PTV2 where PTV2 was the CTV2 (GTV + high-risk regions) + 0.5 cm margin (range NS)

Fung Med Dosim 2012 [19]

10 (10 NPC)

Fx 21, 31 approx.

–

–

53.95% CTV, 36.19% PTV where PTV was the CTV + 0.3 cm (range NS)

Jin Radiat Oncol 2013 [20]

9 (9 NPC)

Fx 23

–

–

9.4% GTV by fraction 23 (range NS) (non-sig reduction)

Schwartz Radiother Oncol 2013 [21]

22 (22 OPC)

Daily scans, Weekly recalc

–

5% CTV where CTV was the GTV + high-risk regions (−21 to 13%)

8% CTV (−6 to 19%)

Tan Onco Targets Ther 2013 [22]

20 (20 NPC)

Weekly

–

–

55.3% GTV (range NS)

Fung J Radiat Res 2014 [23]

30 (30 NPC)

Every 2 Fx

–

–

35.7% GTV (range NS)

Huang Radiat Oncol 2015 [24]

19 (19 NPC)

Every 5 Fx

–

–

65.6% GTV (range NS)

Kataria Br J Radiol [25]

36 (21 OPC, 5 Laryng, 10 Hypoph)

Fx 23

–

–

34.0% GTV (range NS)

Zhang Radiother Oncol 2016 [26]

13 (13 OPC)

Weekly

–

–

24.43% CTV70 where CTV70 was GTV + 0.5 cm margin (−12.6 to 62.1%)

3 to 16%

7 to 48%

6 to 66%